Diseases

Alcohol-Related Liver Disease

Hepatitis A & E

Hepatitis B

Hepatitis C

Hepatocellular Carcinoma

Intrahepatic Cholestasis

Liver Abscess

Neonatal Jaundice

Nonalcoholic Fatty Liver Disease

Primary Biliary Cholangitis

Product Highlight - Ravida

13 Sep 2022

Ravidasvir 200 mg tab

Reducing risks and improving long-term outcomes in patients with CHB

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019

Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.

Product Highlight - OZEMPIC

16 Sep 2020

OZEMPIC – Semaglutide 1.34 mg/mL soln for inj